A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 on ClinicalTrials.gov · last registry update 2026-08-24
A small phase 3 — 125 participants, against a typical 424. Due to report February 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants Allocated to Each ISA. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 125
- Started
- 2024-11-18
- Primary completion
- 2027-02 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants Allocated to Each ISA
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.